MedTrace Logo

Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines

NCT00240292 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2010-11-19

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of rosuvastatin (up-titrated to a dose of 40mg/day) compared to placebo on cardiac remodelling, estimated by change in left ventricular ejection fraction on radionuclide ventriculography, at 26 weeks post randomisation from baseline.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Rosuvastatin

Sponsors & Collaborators

Principal Investigators

  • Henry Krum, MBBS PhD FRACP · Clinical Pharmacology, Department of Epidemiology and Preventative Medicine, Monash University, Alfred Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240292 on ClinicalTrials.gov